Meir Schechter

11PUBLICATIONS
15CO-AUTHORS
PharmacogenomicsMolecular targetsAutonomic nervous systemGene expression (incl. microarray and other genome-wide approaches)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 07, 2026
Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort Study.

|Sep 22, 2026
Dementia progression with GLP-1 receptor agonists in people with mild cognitive impairment and type 2 diabetes: target-trial emulation study.

|Jul 23, 2025
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Data.

Alisa Fishkin, Aliza Rozenberg, Meir Schechter

|Jul 18, 2024
Normoalbuminuria-is it normal? The association of urinary albumin within the 'normoalbuminuric' range with adverse cardiovascular and mortality outcomes: A systematic review and meta-analysis.

Dvora R Sehtman-Shachar, Ilan Yanuv, Meir Schechter

|Jun 29, 2023
Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.

Cheli Melzer Cohen, Meir Schechter, Aliza Rozenberg

|Dec 05, 2022
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.

Meir Schechter, Niels Jongs, Glenn M Chertow

Pageof 2

Frequent Collaborators

4 joint publications

Ofri Mosenzon

3 joint publications

Dvora R Sehtman-Shachar

2 joint publications

Glenn M Chertow

2 joint publications

Hiddo J L Heerspink